Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy)

被引：0

作者：

Massimo Aglietta

Vanna Chiarion-Sileni

Paolo Fava

Massimo Guidoboni

Roberta Depenni

Alessandro Minisini

Francesca Consoli

Paolo Ascierto

Gaetana Rinaldi

Maria Banzi

Riccardo Marconcini

Rossana Gueli

Virginia Ferraresi

Marco Tucci

Giuseppe Tonini

Giovanni Lo Re

Michele Guida

Michele Del Vecchio

Ilaria Gioia Marcon

Paola Queirolo

机构：

[1] University of Torino,Department of Oncology

[2] Candiolo Cancer Institute,Department of Medical Oncology

[3] FPO-IRCCS,Department of Clinical Oncology

[4] Veneto Institute of Oncology IOV-IRCCS,Dermatologic Clinic, Department of Medical Sciences

[5] University of Turin,Immunotherapy

[6] IRCCS-IRST,Cell Therapy and Biobank

[7] University Hospital of Modena and Reggio Emilia,Department of Oncology and Hematology

[8] Azienda Sanitaria Universitaria del Friuli Centrale,Department of Oncology

[9] ASST Spedali Civili,Department of Oncology

[10] Istituto Nazionale Tumori IRCCS Fondazione Pascale,Department of Melanoma, Cancer Immunotherapy and Development Therapeutics

[11] UOC Oncologia Medica Aoup Paolo Giaccone,Oncology Unit

[12] Presidio Ospedaliero Arcispedale Santa Maria Nuova AUSL di Reggio Emilia-IRCCS,Medical Oncology

[13] Presidio Ospedaliero S. Chiara-Az. Ospedaliero Universitaria Pisana,Sarcomas and Rare Tumors Unit

[14] ASST Sette Laghi,Department of Biomedical Sciences and Clinical Oncology

[15] Circolo Hospital and Macchi Foundation,Department of Medical Oncology

[16] IRCCS‐Regina Elena National Cancer Institute,Rare Tumors and Melanoma Unit

[17] University of Bari,Unit of Melanoma Medical Oncology, Department of Medical Oncology and Hematology

[18] “Aldo Moro”,Oncology Division

[19] University Campus Bio-Medico,Division of Medical Oncology for Melanoma, Sarcoma, and Rare Tumors

[20] Oncologia Medica e dei Tumori Immunocorrelati,undefined

[21] CRO Aviano IRCCS,undefined

[22] IRCCS Istituto dei Tumori “Giovanni Paolo II”,undefined

[23] Fondazione IRCCS Istituto Nazionale dei Tumori,undefined

[24] Novartis Farma S.p.A,undefined

[25] Policlinico San Martino IRCCS,undefined

[26] IEO,undefined

[27] European Institute of Oncology IRCCS,undefined

来源：

Targeted Oncology | 2021年 / 16卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：789 / 799

页数：10

共 50 条

[1] Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy)
Aglietta, Massimo
Chiarion-Sileni, Vanna
Fava, Paolo
Guidoboni, Massimo
Depenni, Roberta
Minisini, Alessandro
Consoli, Francesca
Ascierto, Paolo
Rinaldi, Gaetana
Banzi, Maria
Marconcini, Riccardo
Gueli, Rossana
Ferraresi, Virginia
Tucci, Marco
Tonini, Giuseppe
Lo Re, Giovanni
Guida, Michele
Del Vecchio, Michele
Marcon, Ilaria Gioia
Queirolo, Paola
[J]. TARGETED ONCOLOGY, 2021, 16 (06) : 789 - 799
[2] Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II)
Atkinson, Victoria
Sandhu, Shahneen
Hospers, Geke
Long, Georgina, V
Aglietta, Massimo
Ferrucci, Pier F.
Tulyte, Skaiste
Cappellini, Gian Carlo Antonini
Soriano, Virtudes
Ali, Sayed
Poprach, Alexandr
Cesas, Alvydas
Rodriguez-Abreu, Delvys
Lau, Mike
de Jong, Egbert
Legenne, Philippe
Stein, Dara
King, Brianna
van Thienen, Johannes, V
[J]. MELANOMA RESEARCH, 2020, 30 (03) : 261 - 267
[3] Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma
Dummer, Reinhard
Long, Georgina V.
Robert, Caroline
Tawbi, Hussein A.
Flaherty, Keith T.
Ascierto, Paolo A.
Nathan, Paul D.
Rutkowski, Piotr
Leonov, Oleg
Dutriaux, Caroline
Mandala, Mario
Lorigan, Paul
Ferrucci, Pier Francesco
Grob, Jean Jacques
Meyer, Nicolas
Gogas, Helen
Stroyakovskiy, Daniil
Arance, Ana
Brase, Jan C.
Green, Steven
Haas, Tomas
Masood, Aisha
Gasal, Eduard
Ribas, Antoni
Schadendorf, Dirk
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (13) : 1428 - +
[4] Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib
Long, Georgina V.
Weber, Jeffrey S.
Infante, Jeffrey R.
Kim, Kevin B.
Daud, Adil
Gonzalez, Rene
Sosman, Jeffrey A.
Hamid, Omid
Schuchter, Lynn
Cebon, Jonathan
Kefford, Richard F.
Lawrence, Donald
Kudchadkar, Ragini
Burris, Howard A., III
Falchook, Gerald S.
Algazi, Alain
Lewis, Karl
Puzanov, Igor
Ibrahim, Nageatte
Sun, Peng
Cunningham, Elizabeth
Kline, Amy S.
Buono, HeatherDel
OpattMcDowell, Diane
Patel, Kiran
Flaherty, Keith T.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (08) : 871 - +
[5] Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib
Long, Georgina, V
Eroglu, Zeynep
Infante, Jeffrey
Patel, Sapna
Daud, Adil
Johnson, Douglas B.
Gonzalez, Rene
Kefford, Richard
Hamid, Omid
Schuchter, Lynn
Cebon, Jonathan
Sharfman, William
McWilliams, Robert
Sznol, Mario
Redhu, Suman
Gasal, Eduard
Mookerjee, Bijoyesh
Weber, Jeffrey
Flaherty, Keith T.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (07) : 667 - +
[6] Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib
Jansen, Yanina J.
Janssens, Peter
Hoorens, Anne
Schreuer, Max S.
Seremet, Teofila
Wilgenhof, Sofie
Neyns, Bart
[J]. MELANOMA RESEARCH, 2015, 25 (06) : 550 - 554
[7] Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer
Subbiah, Vivek
Kreitman, Robert J.
Wainberg, Zev A.
Cho, Jae Yong
Schellens, Jan H. M.
Soria, Jean Charles
Wen, Patrick Y.
Zielinski, Christoph
Cabanillas, Maria E.
Urbanowitz, Gladys
Mookerjee, Bijoyesh
Wang, Dazhe
Rangwala, Fatima
Keam, Bhumsuk
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (01) : 7 - +
[8] COMBI-r: A Prospective, Non-Interventional Study of Dabrafenib Plus Trametinib in Unselected Patients with Unresectable or Metastatic BRAF V600-Mutant Melanoma
Berking, Carola
Livingstone, Elisabeth
Debus, Dirk
Loquai, Carmen
Weichenthal, Michael
Leiter, Ulrike
Kiecker, Felix
Mohr, Peter
Eigentler, Thomas K.
Remy, Janina
Schober, Katharina
Heppt, Markus V.
von Wasielewski, Imke
Schadendorf, Dirk
Gutzmer, Ralf
[J]. CANCERS, 2023, 15 (18)
[9] A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III)
Atkinson, Victoria G.
Quaglino, Pietro
Aglietta, Massimo
Del Vecchio, Michele
Depenni, Roberta
Consoli, Francesca
Bafaloukos, Dimitrios
Ferrucci, Pier Francesco
Tulyte, Skaiste
Krajsova, Ivana
Ascierto, Paolo A.
Gueli, Rossana
Arance, Ana
Gogas, Helen
Banerjee, Hiya
Saliba, Teddy
de Jong, Egbert
Neyns, Bart
[J]. CANCERS, 2021, 13 (10)
[10] Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF V600 Mutation
Dhillon, Sohita
[J]. TARGETED ONCOLOGY, 2016, 11 (03) : 417 - 428

← 1 2 3 4 5 →